T7582

Tafamidis meglumine (Fx-1006A) is a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade.

TAT-Gap19 TFA, a Cx mimetic peptide and specific connexin43 hemichannel (Cx43 HC) inhibitor, does not inhibit corresponding Cx43 gap junction channels (GJCs). It crosses the blood-brain barrier and has shown efficacy in alleviating liver fibrosis in mice [1] [2] [3].

GLP-1(9-36)amide TFA, a predominant metabolite of glucagon-like peptide-1-(7-36)amide synthesized through dipeptidyl peptidase-4 (DPP-4) activity, functions as an antagonist to the human pancreatic GLP-1 receptor [1] [2].

Bay 55-9837 TFA, a potent and highly selective VPAC2 agonist with a dissociation constant (Kd) of 0.65 nM, represents a potential research therapy for type 2 diabetes [1].

D[LEU4,LYS8]-VP TFA is a selective agonist for the vasopressin V1b receptor, with Ki values of 0.16 nM for rat, 0.52 nM for human, and 1.38 nM for mouse V1b receptors. This compound exhibits limited antidiuretic, vasopressor, and oxytocic activities in vitro [1] [2].

UFP-803 TFA, a potent ligand for the urotensin-II receptor (UT), exhibits minimal residual agonist activity, rendering it a valuable asset for exploring the UT system's function in physiology and pathology [1].

[Orn5]-URP TFA acts as a potent and selective antagonist exclusively targeting the Urotensin-II receptor (UT), devoid of any agonist activity, and demonstrates a significant inhibitory efficiency with a pEC50 value of 7.24 [1] [2].